Study On The Expressions Of HER-2, EBP1Protein And Mrna In Colorectal Carcinoma And Its Clinical Significance

Colorectal cancer is one of the most common malignant tumors which can hazard human health in the world. The study of Its pathogenesis and treatment was one of the clinical basic researches all the time. The thesis explores the relationship between the expressions of HER-2and Ebp1in colorectal cancer and clinicopathological features. It also analyzes the relationship between the expressions of HER-2and Ebp1. To investigate the role and the possible mechanism of the HER-2and Ebpl protein in colorectal tumorigenesis process in order to provide a theoretical basis for the diagnosis and treatment of colorectal cancer.65operative specimens of colorectal cancer admitted to Department of General Surgery in309Hospital PLA from Jan.2010to Dec.2011are selected as the experimental group/Group A. The65patients consisted of38males and27females, whose ages ranged from35to81with an average age of53.24. The TNM stages are:10cases of stage Ⅰ,24cases of stage Ⅱ and31cases of stage Ⅲ. The degree of differentiation are:29cases of low differentiation,24cases of medium differentiation and12cases of high differentiation.40cases had metastasis to lymph nodes and25cases had not. In addition,60cases of normal colorectal mucosa are selected as the control group(Group B). Immunohistochemistry (EnVision method) and chromogenic in situ hybridization are used to detect the expression of HER-2, Ebpl protein and mRNA of the two groups.1. HER-2, Ebp1protein and mRNA expression are observed mainly in cytoplasm. The positive stains are yellow or brown signals.The positive rates of HER-2, Ebp1protein and mRNA expression in colorectal cancer (Group A) are64.62%(42/65),69.23%(45/65),9.23%(6/65),12.31 %(8/65) respectively. The positive rates of HER-2, Ebp1protein and mRNA expression in normal colorectal mucosa (Group B) are23.43%(14/60),26.67%(16/60),81.67%(49/60),85.00%(51/60) respectively. HER-2protein and mRNA are overexpressed in colorectal cancer (Group A) compared with those in normal colorectal mucosa(Group B), while Ebp1protein and mRNA are underexpressed in colorectal cancer (Group A) compared with those in normal colorectal mucosa(Group B)(P<0.05).2. The expression of HER-2, Ebpl protein and mRNA are not related to age, sex and family tumor history of the patient(P>0.05). The expressions of HER-2, Ebp1protein and mRNA have a close correlation with the TNM staging, tumor differentiation, and lymphatic metastasis of colorectal cancer. The positive expression of HER-2. protein and mRNA are positively correlated with the TNM staging, tumor differentiation, lymphatic metastasis of colorectal cancer(P<0.05). The positive expression of Ebpl protein and mRNA are negatively correlated with the TNM staging, tumor differentiation, lymphatic metastasis of colorectal cancer(P<0.05).3. In the42cases colorectal cancer tissue with positive expression of HER-2protein, there is only1case of positive expression of Ebpl protein and41cases of negative expression of Ebpl protein. In the23cases colorectal cancer tissue with negative expression of HER-2protein, there are5case of positive expression of Ebpl protein and18cases of negative expression of Ebp1protein. In the45cases colorectal cancer tissue with positive expression of HER-2mRNA, there is1case of positive expression of Ebp1mRNA and41of cases negative expression of Ebp1mRNA. In the23cases colorectal cancer tissue with negative expression of HER-2mRNA, there are5cases of positive expression of Ebp1mRNA and18cases of negative expression of Ebp1mRNA. The expressions of HER-2and Ebp1protein and mRNA in colorectal cancer tissue are negatively relative(R=-0.26,P<0.05). The expression of HER-2, Ebp1protein and mRNA are not related to age, sex and family tumor history of the patient, and have a close correlation with the TNM staging, tumor differentiation, and lymphatic metastasis of colorectal cancer. HER-2and Ebp1can be used as biologic tumor markers of monitoring disease progression, metastatic potential and prognostic evaluation in colorectal cancer. The expressions of HER-2and Ebp1are negatively relative, which suggested that they have a collaborative effect on pathological process of occurrence and development, the clinical progress and metastasis in colorectal cancer. Co-detection of HER-2and Ebp1might have important significance to evaluate the cell proliferation differentiation and metastasis of the tumors. The Ebp1may be a new marker of potential therapeutic target in the colorectal carcinoma.